Drug Delivery Technologies: Players, products & prospects to 2015

Table of Contents

• EXECUTIVE SUMMARY
  • Competitor Ratio Analysis Summary
• INTRODUCTION
• OVERVIEW OF CONTROLLED-RELEASE DELIVERY: PAST, PRESENT & FUTURE
  • Controlled-Release delivery: motivators & resistors
    • Motivators
    • Resistors
  • Controlled-Release delivery: impact on product lifecycles
• CONTROLLED-RELEASE DELIVERY
  • Types of controlled-release delivery used by pharma industry
    • Activated controlled-release delivery
      • Figure 1: Activated controlled-release delivery - ALZA' s OROS systems
    • Degradation controlled-release delivery
      • Figure 2: Degradation controlled-release delivery - SkyePharma' s GEOMATRIX
    • Diffusion controlled-release delivery
      • Figure 3: Monolithic diffusion controlled-release delivery - LaboPharm' s Contramid
      • Figure 4: Reservoir diffusion controlled-release delivery - Impax' CMDS
      • Figure 5: Combined controlled-release delivery - Flamel' s Micropump
      • Table 1: Advantages and disadvantages of controlled-release platforms
  • Current therapeutic application of controlled-release in drug delivery
  • Leading brands that utilise controlled-release delivery
    • Table 2: Controlled-Release approved drugs
  • Future commercial applications & opportunities
• STRATEGIES OF DRUG DELIVERY COMPANIES
  • Leading controlled-release drug delivery companies
    • Table 3: Leading controlled-release drug delivery companies
  • Partnerships & acquisitions
    • Strategic developmental & commercialisation partnerships
    • Merger & acquisitions
      • Table 4: Recent partnerships & acquisitions in the controlled-release field
  • Intellectual Property
    • Table 5: Controlled-Release patents
  • THE controlled-release MARKET
    • Now 2007
      • Table 6: Approved controlled-release product sales
    • Future 2015
      • Table 7: Global controlled-release product sales
      • Table 8: Novel controlled-release product sales
• COMPETITOR ANALYSIS
  • Movers & Shakers: Cutting edge or losing their grip
    • Table 9: Movers & shakers in controlled-release drug delivery systems
• COMPANY PROFILES
  • AlphaRx Corporation
    • Table 10: AlphaRx' product pipeline
    • Table 11: AlphaRx' drug delivery sales
  • ALZA Corporation
    • Table 12: ALZA' s product pipeline
    • Table 13: ALZA' s drug delivery sales
  • Andrx Corporation
    • Table 14: Andrx' product pipeline
    • Table 15: Andrx' drug delivery sales
  • Antares Pharma, Inc.
    • Table 16: Antares' product pipeline
    • Table 17: Antares' drug delivery sales
  • Biovail International
    • Table 18: Biovail' s product pipeline
    • Table 19: Biovail' s drug delivery sales
  • Camurus AB
    • Table 20: Camurus AB' s product pipeline
    • Table 21: Camurus AB' s drug delivery sales
  • Cipher Pharmaceuticals, Inc.
    • Table 22: Cipher' s product pipeline
    • Table 23: Cipher' s drug delivery sales
  • Debiopharm
    • Table 24: Debiopharm' s product pipeline
    • Table 25: DebioPharm' s drug delivery sales
  • DelSite Biotechnologies, Inc.
    • Table 26: DelSite' s product pipeline
  • Depomed, Inc.
    • Table 27: Depomed' s product pipeline
    • Table 28: Depomed' s product sales
  • Durect Corporation
    • Table 29: Durect' s product pipeline
    • Table 30: Durect' s product sales
  • Eiffel Technologies
    • Table 31: Eiffel' s product pipeline
  • Elan Corporation
    • Table 32: Elan' s product pipeline
    • Table 33: Elan' s drug delivery sales
  • Elite Pharmaceuticals, Inc.
    • Table 34: Elite' s product pipeline
    • Table 35: Elite' s product sales
  • Endo Pharmaceuticals, Inc.
    • Table 36: Endo' s product pipeline
    • Table 37: Endo' s product sales
  • Ethypharm SA
    • Table 38: Ethypharm' s product pipeline
    • Table 39: Ethypharm' s product sales
  • Eurand
    • Table 40: Eurand' s product pipeline
    • Table 41: Eurand' s product sales
  • Flamel Technologies, Inc.
    • Table 42: Flamel' s product pipeline
    • Table 43: Flamel' s product sales
  • Glycologic, Ltd.
    • Table 44: Glycologic' s product pipeline
  • Impax Laboratories, Inc.
    • Table 45: Impax' product pipeline
    • Table 46: Impax' s product sales.
  • KV Pharmaceuticals, Inc.
    • Table 47: KV' s product pipeline
  • Labopharm, Inc.
    • Table 48: Labopharm' s product pipeline
    • Table 49: Labopharm' s product sales
  • Lavipharm SA
    • Table 50: Lavipharm' s product pipeline
    • Table 51: Lavipharm' s product sales
  • OctoPlus N.V.
    • Table 52: Octoplus' product pipeline
    • Table 53: Octoplus' product sales
  • Penwest Pharmaceuticals
    • Table 54: Penwest' s product pipeline
    • Table 55: Penwest' s product sales
  • Protherics
    • Table 56: Protherics' product pipeline
    • Table 57: Protherics' drug delivery sales
  • SCOLR Pharma, Inc.
    • Table 58: SCOLR' s product pipeline
    • Table 59: SCOLR' s drug delivery sales
  • Shire
    • Table 60: Shire' s product pipeline
    • Table 61: Shire' s drug delivery sales
  • Skinvisible, Inc.
    • Table 62: Skinvisible' s product pipeline
  • SkyePharma
    • Table 63: SkyePharma' s CR product pipeline
    • Table 64: SkyePharma' s controlled-release product sales
  • Spherics
    • Table 65: Spheric' s product pipeline
• APPENDIX 1
  • Table 66: Global controlled-release approved drugs sales 2006A-20015E
• APPENDIX 2
  • Table 67: Global controlled-release developmental drugs sales 2006A-20015E
• APPENDIX 3
  • Competitor Ratio Analysis Criteria
    • Table 68: Key Controlled-Release delivery companies by 2015
• BIBLIOGRAPHY
• GLOSSARY
• ACRON YMS

• EXECUTIVE SUMMARY
  • Competitor Ratio Analysis Summary
• INTRODUCTION
• Overview of nanotechnology: past, present & future
  • Figure 1: Top ten applications of nanotechnology in developing countries
  • Nanotechnology: motivators & resistors
    • Motivators
    • Resistors
  • Nanotechnology: impact on product lifecycles
• NANO TECHNOLOGY IN DRUG DELIVERY
  • Core nanotechnology used by the pharma industry
    • Nano-engineered drugs
    • Nano-carriers
      • Figure 2: Dendrimer structure
      • Figure 3: Liposome structure
      • Figure 4: Micelle structure
  • Current therapeutic application of nanotechnology in drug delivery
    • Leading brands that utilise nanotechnology delivery
      • Table 1: Nanotechnology-enabled approved drugs
    • Future commercial applications & opportunities
• STRATEGIES OF DRUG DELIVERY COMPANIES
  • Leading nanotechnology drug delivery companies
    • Table 2: Leading nanotechnology-enabled drug delivery companies
  • Partnerships & acquisitions
    • Strategic development & commercialisation partnerships and joint ventures
      • Table 3: Recent partnerships & acquisitions in the nanotechnology field
    • Mergers & acquisitions
      • Table 4: Nanotechnology patents
• THE NANO TECHNOLOGY MARKET
  • Now 2007
    • Table 5: Approved nano-enabled product sales
  • Future 2015
    • Table 6: Novel nano-enabled product sales
    • Table 7: Global nano-enabled product sales
• COMPETITOR ANALYSIS
  • Movers & Shakers: Cutting edge or losing their grip
    • Table 8: Movers & shakers in nanotechnology drug delivery systems
• COMPANY PROFILES
  • Abraxis Bioscience
    • Table 9: Abraxis' product pipeline
    • Table 10: Abraxis Drug Delivery Sales
  • Access Pharmaceuticals
    • Table 11: Access Pharmaceuticals product pipeline
  • AlphaRx Corporation
    • Table 12: AlphaRx' product pipeline
    • Table 13: AlphaRx' pharmaceuticals drug delivery sales
  • ALZA Corporation
    • Table 14: ALZA' s drug delivery sales
  • BioSante Pharmaceuticals
    • Table 15: BioSante' s product pipeline
    • Table 16: BioSante' s drug delivery sales
  • Camurus AB
    • Table 17: Camurus AB' s product pipeline
    • Table 18: Camurus AB' s drug delivery sales
  • Eiffel Technologies
    • Table 19: Eiffel' s product pipeline
  • Elan Corporation
    • Table 20: Elan' s product pipeline
    • Table 21: Elan' s drug delivery sales
  • Eurand
    • Table 22: Eurand' s product pipeline
  • Gilead Sciences
    • Table 23: Gilead Sciences' product pipeline
    • Table 24: Gilead Sciences' drug delivery sales
  • Nano Interface Technology
    • Table 25: NITI' s product pipeline
  • Nano S Biotechnology GmbH
    • Table 26: Nano S' product pipeline
  • NanoBio Corporation
    • Table 27: NanoBio' s product pipeline
    • Table 28: NanoBio' s drug delivery sales
  • NanoBioMagnetics
    • Table 29: NanoBioMagnetics' product pipeline
  • Nanobiotix
    • Table 30: Nanobiotix' product pipeline
  • NanoCarrier
    • Table 31: NanoCarrier' s product pipeline
    • Table 32: NanoCarrier' s drug delivery sales
  • Nanotechnology Victoria, Ltd.
    • Table 33: NanoVic' s product pipeline
  • NanoMaterials Technology
    • Table 34: NanoMaterial' s product pipeline
  • Nanotherapeutics
    • Table 35: Nanotherapeutics' product pipeline
    • Table 36: Nanotherapeutics' drug delivery sales
  • Novavax
    • Table 37: Novavax' s product pipeline
    • Table 38: Novavax' s drug delivery sales
  • SkyePharma
    • Table 39: SkyePharma' s product pipeline
    • Table 40: SkyePharma' s product sales
  • Spherics
    • Table 41: Spheric' s product pipeline
• APPENDIX 1
  • Table 42: Global nanotechnology approved drugs sales 2006A-20015E
• APPENDIX 2
  • Table 43: Global nanotechnology developmental drugs sales 2006A-20015E
• APPENDIX 3
  • Competitor Ratio Analysis Criteria
    • Table 44: Key nanotechnology delivery companies by 2015
• BIBLIOGRAPHY
• GLOSSARY
• ACRONYMS

• EXECUTIVE SUMMARY
  • Competitor Ratio Analysis Summary
• INTRODUCTION
• OVERVIEW OF DELIVERY TECHNOLOGIES FOR GENTIC MATERIAL: PAST, PRESENT & FUTURE
  • Nucleic acid delivery: motivators & resistors
    • Motivators
    • Resistors
• NUCLEIC ACID DELIVERY TECHNOLOGIES
  • Types of nucleic acid based products under development by the pharma industry
    • Viral vector delivery of nucleic acids
      • Figure 1: Schematic of gene therapy utilising an AAV vector
      • Figure 2: Schematic of gene therapy utilising HVJ envelope - virosome
  • Non-viral vector delivery of nucleic acids
    • Figure 3: Stable nucleic acid-lipid particles
    • Figure 4: Targeted nanoparticles
    • Figure 5: Schematic of Macroflux Technology
    • Figure 6: Schematic of PMED Technology and delivery
    • Table 1: Advantages and disadvantages of nucleic acid platforms
  • Current therapeutic applications for the viral and non-viral delivery of nucleic acids
  • Leading nucleic acid based products in development
    • Table 2: Nucleic acid-based approved/filed drugs
    • Table 3: Selection of nucleic acid-based developmental drugs
  • Future commercial applications & opportunities
• STRATEGIES OF DRUG DELIVERY COMPANIES
  • Leading nucleic acid drug delivery companies
    • Table 4: Leading nucleic acid drug delivery specialists
  • Partnerships & acquisitions
    • Strategic developmental & commercialisation partnerships
    • Mergers & acquisitions
      • Table 5: Recent partnerships & acquisitions in the nucleic acid field
  • Intellectual Property
    • Table 6: Nucleic acid patents
• THE VIRAL AND NON-VIRAL VECTOR DELIVERY MARKET
  • Now 2007
    • Table 7: Approved nucleic acid product sales
  • Future 2015
    • Table 8: Global controlled-release product sales
    • Table 9: Novel nucleic acid product sales
• COMPETITOR ANALYSIS
  • Movers & Shakers: Cutting edge or losing their grip
    • Table 10: Movers & shakers in nucleic acid drug delivery systems
• COMPANY PROFILES
  • AlphaVax, Inc.
    • Figure 7: The alphavaccine platform system
    • Table 11: AlphaVax product pipeline
    • Table 12: AlphaVax' sales forecasts (US$ million)
  • Altea Therapeutics, Inc.
    • Table 13: Altea Therapeutics' product pipeline
  • AP Pharma, Inc.
    • Table 14: AP Pharma' s product pipeline
  • Aradigm, Inc.
    • Table 15: Aradigm' s product pipeline
  • BioDelivery Sciences International
    • Figure 8: Bioral Technology
    • Figure 9: Direct membrane fusion
    • Table 16: BDSI' s product pipeline
  • Calando Pharmaceuticals
    • Figure 10: Schematic of cyclodextrin polymeric nanoparticles
    • Table 17: Calando' s product pipeline
    • Table 18: Calando' s sales forecasts
  • Copernicus Therapeutics
    • Figure 11: Uptake and trafficking of condensed nanoparticle DNA
    • Table 19: Copernicus' product pipeline
    • Table 20: Copernicus' sales forecasts
  • Diatos SA
    • Table 21: Diatos' product pipeline
  • DOR BioPharma, Inc.
    • Table 22: DOR' s product pipeline
  • Expression Genetics, Inc.
    • Figure 12: TheraPlas Technology Platform
    • Table 23: EGEN' s product pipeline
    • Table 24: EGEN' s sales forecasts
  • Inovio Biomedical Corporation
    • Figure 13: Inovio' s gene delivery platform
    • Table 25: Inovio' s product pipeline
    • Table 26: Inovio' s sales forecasts
  • Macroflux Corporation
    • Table 27: Macroflux' product pipeline
  • Maxcyte, Inc.
    • Figure 14: MaxCyte' s GT ex-vivo cell loading system
    • Table 28: MaxCyte' s product pipeline
  • Mirus Bio Corporation
    • Figure 15: PolyConjugates - siRNA delivery system
    • Table 29: Mirus' product pipeline
    • Table 30: Mirus' sales forecasts
  • Nanotherapeutics Inc.
    • Table 31: Nanotherapeutics' product pipeline
  • NeoPharm
    • Table 32: NeoPharm' s product pipeline
  • Novagali Pharma SA
    • Table 33: Novagali' s product pipeline
  • PCI Biotech
    • Table 34: PCI' s product pipeline
  • PowderMed Inc
    • Table 35: PowderMed' s product pipeline
    • Table 5.2.25: PowderMed' s sales forecasts
  • Protiva Biotherapeutics, Inc.
    • Table 37: Protiva' s product pipeline
    • Table 38: Protiva' s sales forecasts
  • Silence Therapeutics plc
    • Table 39: Silence Therapeutics' product pipeline
    • Table 40: Silence Therapeutics' sales forecasts
  • Supratek Pharma Inc.
    • Table 40: Supratek' s product pipeline
  • Tekmira Pharmaceuticals Corporation
    • Table 42: Tekmira' s product pipeline
    • Table 43: Tekmira' s sales forecasts
  • Vical Inc.
    • Table 44: Vical' s product pipeline
    • Table 45: Vical' s sales forecasts
• APPENDIX 1
  • Table 46: Global nucleic acid approved drugs sales 2006A-20015E
• APPENDIX 2
  • Table 47: Global nucleic acid developmental drugs sales 2006A-20015E
• APPENDIX 3
  • Competitor Ratio Analysis Criteria
    • Table 48: Key nucleic acid delivery companies by 2015
• BIBLIOGRAPHY
• GLOSSARY
• ACRONYMS
• FOOTNOTE REFERENCES

• EXECUTIVE SUMMARY
  • Competitor Ratio Analysis Summary
• INTRODUCTION
• OVERVIEW OF DELIVERY TECHNOLOGIES FOR SYSTEMIC TARGETED DELIVERY: PAST, PRESENT & FUTURE
  • Systemic targeted delivery: motivators & resistors
  • Motivators
  • Resistors
• SYSTEMIC TARGETED DELIVERY TECHNOLOGIES
  • Types of systemic targeted delivery platform in development in the pharma industry
    • Targeting ligands
      • Figure 1: Antibody-directed enzyme prodrug targeted delivery
      • Figure 2: Peptide-induced release for targeted delivery
      • Figure 3: Nucleomic mediated targeted intranuclear delivery
      • Figure 4: Vitamin mediated targeted intracellular delivery - Cobalamin
  • Non-biological targeting platforms
    • Figure 5: Photosensitive targeted delivery
  • Current therapeutic applications for systemic targeted delivery
  • Leading systemic targeted products in development
    • Table 1: Approved systemic and targeted drugs
  • Future commercial applications & opportunities
• STRATEGIES OF DRUG DELIVERY COMPANIES
  • Leading targeted drug delivery companies
    • Table 2: Leading systemic targeted delivery specialists
  • Partnerships & acquisitions
    • Strategic alliances
    • Strategic acquisitions
      • Table 3: Recent market activity in targeted delivery companies
  • Intellectual Property
    • Table 4: Targeted drug delivery patents
• THE TARGETED DELIVERY MARKET
  • Now 2007
    • Table 5: Approved targeted delivery product sales
  • Future 2015
    • Table 6: Global controlled release product sales
    • Table 7: Novel targeted delivery product sales
• COMPETITOR ANALYSIS
  • Movers & Shakers: Cutting edge or losing their grip
    • Table 8: Movers & shakers in targeted drug delivery systems
• COMPANY PROFILES
  • Access Pharmaceuticals
    • Figure 6: Schematic of targeted nanoparticle
    • Table 9: Targeted delivery of cancer subtypes via folate polymer, Vitamin B12 polymer and biotin polymers
    • Table 10: Access Pharmaceuticals' product pipeline
    • Table 11: Access Pharmaceuticals' targeted delivery sales forecasts
  • ALZA
    • Table 12: ALZA' s product pipeline
    • Table 13: ALZA' s targeted drug delivery sales
• Avidimer Therapeutics
  • Table 14: Avidimer' s product pipeline
  • Table 15: Avidimer' s targeted drug delivery sales
  • Calando Pharmaceuticals
    • Figure 7: Schematic of cyclodextrin polymeric nanoparticles
    • Table 16: Calando' s product pipeline
    • Table 17: Calando' s targeted delivery sales forecasts
  • Cell Therapeutics
    • Figure 8: CTI' s polyglutamate polymer technology
    • Table 18: CTI' s product pipeline
  • Copernicus Therapeutics
    • Table 20: Copernicus' product pipeline
    • Table 21: Copernicus' targeted delivery sales forecasts
  • Diatos SA
    • Table 22: Diatos' product pipeline
    • Table 23: Diatos' targeted drug delivery sales
  • Enzon Pharmaceuticals, Inc.
    • Table 24: Enzon' s product pipeline
    • Table 25: Enzon' s targeted product sales
  • Endocyte Inc.
    • Table 26: Endocyte' s product pipeline
    • Table 27: Endocyte' s targeted drug delivery sales
  • Eurand
    • Table 28: Eurand' s product pipeline
  • ImmunoGen
    • Table 29: ImmunoGen' s product pipeline
    • Table 30: ImmunoGen' s targeted delivery sales
  • ImaRx Therapeutics
    • Table 31: ImaRx' product pipeline
    • Table 32: ImaRx' targeted product sales
  • Insert Therapeutics
    • Figure 9: Schematic of Cyclosert' s nanoparticle mediated drug delivery to solid tumours
    • Table 33: Insert Therapeutics' product pipeline
    • Table 34: Insert Therapeutics' targeted product sales
  • Mirus Bio Corporation
    • Figure 10: PolyConjugates - siRNA delivery system
    • Table 35: Mirus' product pipeline
  • NanoBioMagnetics, Inc
    • Table 36: NanoBioMagnetics' product pipeline
  • Nanobiotix
    • Table 37: Nanobiotix' product pipeline
  • NanoCarrier
    • Figure 11: NanoCoat technology
    • Table 38: NanoCarrier' s product pipeline
    • Table 39: NanoCarrier' s targeted drug delivery sales
  • NeoPharm
    • Table 40: NeoPharm' s product pipeline
    • Table 41: NeoPharm' s drug delivery sales
  • Novosom AG
    • Figure 12: Schematic of SMARTICLES mechanism of targeted delivery
    • Table 42: Novosom' s product pipeline
  • PCI Biotech AS
    • Figure 13: Schematic of principle of PCI technology
    • Table 43: PCI' s product pipeline
  • Point BioMedical Corporation
    • Figure 14: Schematic of Point' s biSphere
    • Table 44: Point' s product pipeline
  • Quest PharmaTech
    • Table 45: Quest PharmaTech' s product pipeline
  • Seattle Genetics
    • Figure 15: Schematic of ADC' s
    • Table 46: Seattle Genetic' s product pipeline
    • Table 47: Seattle Genetic' s delivery sales
  • Starpharma
    • Table 48: Starpharma' s product pipeline
  • Supratek Pharma Inc.
    • Table 49: Supratek' s product pipeline
  • Tekmira Pharmaceuticals Corporation
    • Table 50: Tekmira' s product pipeline
    • Table 51: Tekmira' s targeted delivery sales forecasts
• APPENDIX 1
  • Table 52: Global targeted approved drugs sales 2006A-20015E
• APPENDIX 2
  • Table 53: Global targeted developmental drugs sales 2006A-20015E
• APPENDIX 3
  • Competitor Ratio Analysis Criteria
    • Table 54: Key targeted delivery companies by 2015
• BIBLIOGRAPHY
• GLOSSARY
• ACRONYMS